GSK3903133A
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
March 01, 2024
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=160 | Completed | Sponsor: GlaxoSmithKline | N=82 ➔ 160
Enrollment change • Infectious Disease
August 05, 2022
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1 | N=82 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease
May 18, 2021
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1; N=82; Active, not recruiting; Sponsor: GlaxoSmithKline; Recruiting ➔ Active, not recruiting; Trial completion date: Nov 2022 ➔ Jun 2022
Clinical • Enrollment closed • Trial completion date • Infectious Disease
April 23, 2021
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1; N=110; Recruiting; Sponsor: GlaxoSmithKline; N=160 ➔ 110; Trial completion date: Jul 2022 ➔ Nov 2022; Trial primary completion date: Apr 2021 ➔ Aug 2021
Clinical • Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease
August 27, 2020
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Experimental Rabies Vaccine in Healthy Adults
(clinicaltrials.gov)
- P1; N=160; Recruiting; Sponsor: GlaxoSmithKline; Trial completion date: Aug 2021 ➔ Jul 2022
Trial completion date • Infectious Disease
1 to 5
Of
5
Go to page
1